菜单

Press Releases

WuXi Biologics Included in S&P Global Sustainability Yearbook (China Edition) for Fourth Consecutive Year
June 11, 2026
WuXi Biologics Included in S&P Global Sustainability Yearbook (China Edition) for Fourth Consecutive Year
  • S&P CSA score ranking in Global Top 1%
  • Inclusion in both Global Yearbook and China Yearbook for fourth consecutive year
  • Green CRDMO solutions to empower global clients on their sustainability journeys

 

Shanghai, China, June 11, 2026 – WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been included in the 2026 S&P Global Sustainability Yearbook (China Edition), which was launched at the S&P Global Sustainability Forum in Shanghai recently.

 

Both the S&P Global Sustainability Yearbook and the Sustainability Yearbook (China Edition) are based on the results of the S&P Global Corporate Sustainability Assessment (CSA), recognizing companies with outstanding sustainability performance across their respective industries. In 2026, a total of 1,800 companies were eligible for consideration of China Edition, and only around 190 were ultimately selected for inclusion in the Yearbook.

 

For the fourth consecutive year, WuXi Biologics achieved a CSA score placing it in the Global Top 1% ranking, and was selected for inclusion in both the Global Sustainability Yearbook and the Sustainability Yearbook (China Edition), demonstrating its steadfast commitment to and significant advancements in driving sustainable development.

 

Robert Dornau, Head of Corporate Solutions and Engagement, S&P Global Energy Sustainable1, commented, “We extend our sincere appreciation to all participating companies and to the CSA team at S&P Global. Your commitment, engagement, and rigor make this Yearbook possible—and help raise the standard for transparency and performance worldwide. Thank you for your ongoing commitment to sustainability and for being part of this journey.”

 

Dr. Chris Chen, WuXi Biologics CEO and Chairman of the ESG Committee, commented, “We are very pleased to be once again selected for the China Yearbook, a reflection of our continued dedication to enhancing our sustainability performance. As a global leader in Green CRDMO, we are committed to working collaboratively with all stakeholders to create positive social and environmental impacts, empowering our global clients through end-to-end Green CRDMO solutions, and amplifying responsible practices across the entire value chain.”

 

Over the years, WuXi Biologics’ consistent efforts to promote sustainable development have received notable recognition from leading global ESG rating agencies, including MSCI AAA Ratings; EcoVadis Platinum Medals; a listing in Dow Jones Best‑in‑Class World Index and Emerging Markets Index; “A List” status from CDP for Climate Change, Water Security, and Supplier Engagement Assessment; the highest negligible-risk rating by Morningstar Sustainalytics, and designation as a Sustainalytics industry and regional ESG Leader; inclusion in the FTSE4Good Index Series; a “Prime” designation from ISS ESG Rating; and inclusion in the Hang Seng Corporate Sustainability Benchmark Index.

 

About WuXi Biologics

 

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics—from concept to commercialization—for the benefit of patients worldwide*.

 

With over 13,000 employees in China, the United States, Ireland, Germany, and Singapore — including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence — WuXi Biologics leverages its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to meet clients’ needs. By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company turns data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of April 30, 2026, WuXi Biologics is supporting 982 integrated client projects, including 78 in Phase III and 25 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.

 

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while demonstrating exemplary Environmental, Social and Governance (ESG) practices. Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts, and promote responsible practices that empower the entire value chain. 

 

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

*The winner of the “2026 Biologics CDMO of the Year” (Large CDMOs) (Life Science Connect / Outsourced Pharma)

*The winner of the “2026 Best Contract Development & Manufacturing Organization Award” (ABEA)

 

Contacts

 

ESG

esg@wuxibiologics.com

 

Media

PR@wuxibiologics.com